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Abstract: Pulmonary metastases are common in patients after
resection for nonseminomatous germ cell tumor of the testis. There
is solid evidence that resection for residual pulmonary disease, after
adjuvant chemotherapy, can provide patients with a long-term sur-
vival. This article addresses the issues of patient selection and
prognostic factors with the current review of pulmonary metasta-
sectomy in metastatic nonseminomatous germ cell tumors retrieved
from retrospective studies. In summary, there is a substantial body
of evidence demonstrating that resection of residual lesions after
chemotherapy can be performed safely with a low mortality rate. For
a subset of patients with viable malignant tumor cells after chemo-
therapy, the overall results of a 5-year actuarial survival rate ranged
between 42 and 61%. However, no presurgical algorithm had proven
effective at predicting histologic outcome and, similar to that in
pulmonary metastasectomy in general, no prospective randomized
trials have been conducted to define the role of surgery versus a
nonsurgical treatment regimen.
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Nonseminomatous germ cell tumor (NSGCT) of testic-ular origin is the most common neoplasm in the male
patients younger than 30 years in the United States.1
NSGCT are characterized by a wide dissemination and
high sensitivity to chemotherapy. The lungs and the retro-
peritoneal space are frequently the initial site of metastatic
disease. Approximately 8% of patients with clinical stage
I will develop pulmonary metastases2 and 29.3% develop
retroperitoneal lymph node metastases.3 The histology
consist of embryonal, teratocarcinoma, chorioncarcinoma,
and yolk sac tumors. Multimodality cisplatin-based regi-
men have greatly improved the cure rate after pulmonary
metastasectomy for disseminated NSGCT and the dismal
prognosis of 30% or less 5-year overall survival rate in the
1960s improved to almost 90% since the late 1970s.4
Twenty percent to 30% of patients with advanced disease
relapse or fail to achieve complete response to conven-
tional first-line cisplatin-based chemotherapy.5 The serum
tumor markers (STMs) -fetoprotein and -human chori-
onic gonadotropin are reliable parameters in diagnosing
and managing the disease. These tumor markers should
decrease in accordance with the response to chemo-
therapy.
Persistant radiographic residual masses accompanied
by normalized marker levels in the serum can contain
necrotic tissue only, differentiated teratoma, or undiffer-
entiated tumor with viable tumor cells. At least 33% of
suspected metastatic lesions have a histology significantly
different from the primary cancer.6,7
Metastasectomy in NSGCT illustrates the curative
potential of integrating local with systemic therapies. The
high cure rates have generated a strong bias toward surgi-
cal resection of any residual lesions after chemotherapy in
patients with these cancers.
Current indications for resection in these patients are
(1) absence of response to chemotherapy; (2) partial re-
sponse followed by recurrence while on chemotherapy; (3)
recurrence after standard and second line chemotherapy;
(4) to determine whether residual viable tumor is present;
and (5) to resect enlarging benign teratomatous elements
of the tumor.8
The primary aims of this review are to determine the
role of pulmonary metastasectomy and to determine the
prognostic parameters in patients with NSGCT and to
evaluate the evidence of published contemprary studies on
pulmonary metastasectomy.
CRITERIA FOR SELECTING STUDIES
To ensure that the reviewed surgical series reflected
the outcome for patients treated with modern surgical,
anesthetic, and diagnostic care techniques, we have re-
stricted our qualitative analysis to surgical series reporting
on patients included in the studies no earlier 1980. There
should be a reporting of at least 50 patients in each study.
All eligible English articles in thoracic surgery between
1998 and 2009 were included (Figure 1). Studies were
identified by searching PubMed supplemented by a manual
search of reference lists of retrieved studies. The following
terms and keywords were used: metastases, lung metasta-
ses, pulmonary metastases, resection, surgery, nonsemino-
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matous germ cell (PubMed user query: lung metastases,
germ cell or pulmonary metastases, germ cell or residual
thoracic masses or disseminated nonseminomatous and
Surgery and ((“1998/01/01”[EDat]:“2009/10/01”[EDat])
and (Humans[Mesh]) and (English[lang])).
RESULTS
Six studies including 407 patients investigated pul-
monary metastasectomy in NSGCT and addressed the
outcome and prognostic variables after resection of pul-
monary metastases (Table 1). The study period was be-
tween 5 and 23 years.6,9 –13 Most studies reported on
patients with pulmonary metastases and retroperitoneal or
mediastinal lymph node residual masses.
Mediastinal lymph node metastases in various num-
bers were reported in all studies. Fizazi et al.,6 Besse et
al.,9 McGuire et al.,12 and Kesler et al.11 reported on the
results of retroperitoneal lymph node dissection. Patients
were highly selected in three single-center and three mul-
ticenter studies.
Three studies6,10,13 distinguished between R0 (no
residual disease) and R1/2 resections (histologic involved
margins/macroscopic residual disease), with a complete
resection rate between 78.5 and 87%. First, surgical resec-
tion of residual masses was performed after adjuvant
chemotherapy in most patients, and in the study by Kesler
et al.,11 salvage operations (elevated postchemotherapy
STM) were solely performed to remove malignant in-
trathoracic disease.
Postoperative Mortality
Between 0.0 and 3.6% death within 30 days of
pulmonary resection was reported by Pfannschmidt et al.,13
Cagini et al.,10 and Kesler et al.11
Overall Survival
Overall survival of 5 years for all patients undergo-
ing resection of pulmonary and/or mediastinal metastases
was reported between 73 and 94%.6,9,10,13 Kesler et al.11
reported a median survival in a group of patients after
salvage surgery of 5.6 years.
Several studies concerning surgery for residual pul-
monary masses from metastatic nonseminomatous testicu-
lar germ cell tumors have been published in the past
decades, and the 5-year survival rates reported ranged from
59 to 82%.4,14–16 In this review of contemporary investi-
gations, 5-year survival rates in patients undergoing resec-
tion of pulmonary and/or mediastinal metastases were
reported between 73 and 94%,6,9,10,13 thus the evolvement
of multimodality treatment regimes lead to a further im-
provement in long-term survival.
MANAGEMENT STRATEGIES
Treatment of patients with residual masses after
chemotherapy is controversial because the histology of the
FIGURE 1. Flow chart of papers found and progressive selection of data.
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resected specimen often revealed necrosis. Yet to date, no
parameter has been established to identify whether pulmo-
nary masses contain necrosis, teratomas, or viable tumor
cells before surgery. Although shrinkage of metastatic
lesions after chemotherapy is well correlated with the
percentage of complete necrosis in retroperitoneal masses,
there is no correlation in pulmonary metastases.9
Therefore, it is generally an aggressive surgical re-
section of all radiographically suspicious lesions recom-
mended for its prognostic utility alone. Radical resection
of NSGCT metastases has been recommended by Cagini et
al.,10 Fizazi et al.,6 and Pfannschmidt et al.13
Resection of mature teratomas is important because
they may undergo malignant transformation.17 Moreover,
the risk of a growing teratoma syndrome makes early
surgical resection advisable.18
Number of Metastases
In the reviewed articles, the number of pulmonary
metastases was of prognostic significance in the study by
Kesler et al.11 They reported on a significantly better
survival in patients who had removed only a solitary
metastasis compared with more than four metastases. So
far, number of lesions has not been found to be statistically
related to prognosis in most other publications.
International Germ Cell Cancer Collaborative
Group
A good classification based on the International
Germ Cell Cancer Collaborative (IGCCC) group was as-
sociated with a favorable prognosis in patients after resec-
tion of metastases with viable malignant cells in a study by
Fizazi et al.6 For the first time in the literature, they
showed the impact of IGCCC subgrouping on long-term
survival after resection of thoracic residual malignant
tumor lesions.
Viable Malignant Tumor Cells
The presence of viable malignant tumor cells in
completely resected residual masses has been designated a
surgical complete resection, but it carries an adverse long-
term prognosis.19–21
Fizazi et al.6 reported on a series of 211 of 238
patients, Pfannschmidt et al.13 reported on a series of 22 of
52 patients, and Cagini et al.10 reported on a series of 46 of
141 patients with viable malignant elements and 5-year
survival rates of 61, 49.6, and 51%, respectively. Kesler et
al.11 reported on a series of 134 patients with salvage
surgery with an estimated 42% 5-year survival rate. Nota-
bly, to remove solely malignant residual pulmonary me-
tastases, salvage surgery was found to have a statistically
inferior prognosis versus patients who underwent medias-
tinal metastasectomy.11 However, an aggressive surgical
approach is justified with prolonged survival being
possible.
How to manage patients with surgical complete re-
section has been a subject of debate. Since the 1980s,20
many authors advocate the use of adjuvant chemotherapy
and this approach has been used to try to improve out-
comes. Many patients retain a degree of chemosensitivity
and thus justified the treatment regimen with chemoth-
erapy.22–25 Others have not shown an improvement in
survival rate most likely due to resistant tumor cells.26
TABLE 1. Studies Reporting on Patients With Resections
Author
Institution
Recruitment
Period
Selection of
Patients
Characteristics of
Patients
Median
Follow-Up
Postoperative
Mortality
5-yr
Survival
Prognostic
Factors
Besse et al.,9
multicenter
1980–2003 71 pts. (PM: 53 pts.) Age range (median):
17–43 (26.8) yr,
Histology,
necrosis: 31%
5.6 yr OS: 94% PFS:
65%
Cagini et al.,10
multicenter
1980–1997 141 pts. (PM: 73 pts.) Age range (median):
16–58 (29.2) yr,
Histology,
necrosis: 23%
44.5 mo 2% (2 pts.) OS: 78% Radicality, histology:
malignant teratoma
Fizazi et al.,33
multicenter
1980–1996 238 pts. (PM: 61 pts.) Age range (median):
14–51 (26.7) yr,
Histology,
necrosis: 0%
7.2 yr OS: 73% PFS:
64%
Radicality resection,
proportion viable
malignant cells,
IGCCC status
Kesler et al.,11
single center
1981–2001 134 pts. (PM: 59 pts.) Age range (median):
14–57 (27.8) yr,
Histology,
necrosis: 0%
5.1 yr (mean) 3.6% (4 pts.) Median OS:
5.6 yr
Age, PM vs.
mediastinal mets,
number mets
McGuire et al.,12
single center
1988–1998 105 pts. (PM: ?) Age range (median):
n.s (n.s.) Histology,
necrosis: 47%
24 mo
Pfannschmidt et al.,13
single center
1996–2001 51 pts, (PM: 51 pts.) Age range (median):
15–46 (29.9) yr,
Histology,
necrosis: 45.1%
80.3 mo 0% OS: 75.8% Radicality, STM
level
PM, pulmonary metastases; OS, overall survival; PFS, progression-free survival; IGCCC, International Germ Cell Cancer Collaborative; STM, serum tumor marker.
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Serum Tumor Marker
Steyerberg et al.24 reported in 1993 that an increased
prechemotherapy level of serum hCG showed a significant
adverse effect on survival, and the importance of increased
STM was also confirmed by Pfannschmidt et al.13 and
others.27 Patients with degenerative nongerm cell carci-
noma do not frequently demonstrate increased STM levels;
therefore, it is not surprising that increased STM level did
not predict outcome in all studies retrieved. In patients
with preoperative normalization of STM after chemother-
apy, complete necrosis/fibrosis is found in residual lung
masses between 54 and 71%.12,28,29
New methods are being investigated in the attempt to
predict the histology of residual masses and avoid surgery
in patients who are already cured by chemotherapy. The
role of positron emission tomography to differentiate be-
tween different pathologies is under investigation. In con-
junction with conventional staging methods, it may offer
additional information.30 Nevertheless, there are major
limitations, because no correlation between complete ne-
crosis and the positron emission tomography tracer uptake
could be found in 37 to 58% of patients.31,32 Thus, positron
emission tomography can only be one valuable adjunct in
the determination of which patients should undergo
postchemotherapy resection.
Surveillance or acting on the findings of retroperito-
neal residual tumor masses after surgery is under discus-
sion. In comparative pathologic studies of retroperitoneal
lymph node dissection specimens and lung metastases, a
discordance rate in lesion components was found between
28 and 36%.12,21,28,29 However, there seems to be a simi-
larity in pathologic findings between residual retroperito-
neal and mediastinal masses,9 which is most likely ex-
plained by the route of lymphatic drainage from the
retroperitoneum via the thoracic duct.
To assess the need for postchemotherapy contralat-
eral resection in patients with ipsilateral complete necro-
sis, Besse et al.9 evaluated 71 patients and their pathologic
finding in residual masses. Among patients who had ne-
crosis only in residual masses from their first lung, 95%
also had necrosis in the contralateral lung. They concluded
that avoiding contralateral lung surgery could therefore be
considered when complete necrosis is found in the first
lung.
CONCLUSION
Metastasectomy in NSGCT illustrates the curative
potential of integrating local with systemic therapies. The
high cure rates have generated a strong bias toward surgi-
cal resection of any residual lesions after chemotherapy in
patients with these cancers.
There are several prognostic parameters for long-
term survival, defined by multivariate analysis in patient
with postchemotherapy thoracic disseminated disease: one
group of factors is related to the initial tumor characteris-
tics (IGCCC group) and prethoracotomy STM levels, the
second group is related to the efficiency of chemotherapy
(histology and number of metastases), and the third group
of parameters is related to the surgical management,
namely the radicality of surgical resection.
However, no presurgical algorithm has proven effec-
tive at predicting histologic outcome and, similar to that in
pulmonary metastasectomy in general, no prospective ran-
domized trials have been conducted to define the role of
surgery versus a nonsurgical treatment regimen. It is dif-
ficult to quantify the survival advantage conferred by
surgical control of disease recurrence in the thorax, be-
cause the cure rate for germ-cell cancers after a pulmonary
metastasectomy is favorable. In addition, surgical resec-
tion is already routinely a part of the multimodal manage-
ment of these patients, which makes the realization of
further prospective randomized studies challenging.
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